These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 29564543)

  • 1. Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center.
    Xue X; Jiang L; Duenninger E; Muenzel M; Guan S; Fazakas A; Cheng F; Illnitzky J; Keil T; Yu J
    Heart Vessels; 2018 Sep; 33(9):1068-1075. PubMed ID: 29564543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of left atrial appendage closure in non-valvular atrial fibrillation in patients over 75 years.
    Yu J; Chen H; Post F; Muenzel M; Keil T; Hou CR; Zhao M; Meng Z; Jiang L
    Heart Vessels; 2019 Nov; 34(11):1858-1865. PubMed ID: 31144099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
    Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
    J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure.
    Guérios ÊE; Chamié F; Montenegro M; Saad EB; Brito FS; Caramori PA; Simões LC; Oliveira FRA; Giuliano LC; Tavares CMDF
    Arq Bras Cardiol; 2017 Nov; 109(5):440-447. PubMed ID: 29069203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry.
    Wintgens L; Romanov A; Phillips K; Ballesteros G; Swaans M; Folkeringa R; Garcia-Bolao I; Pokushalov E; Boersma L
    Europace; 2018 Nov; 20(11):1783-1789. PubMed ID: 29547906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry.
    Fastner C; Brachmann J; Lewalter T; Zeymer U; Sievert H; Borggrefe M; Nienaber CA; Weiß C; Pleger ST; Ince H; Maier J; Achenbach S; Sigusch HH; Hochadel M; Schneider S; Senges J; Akin I
    Clin Res Cardiol; 2021 Jan; 110(1):12-20. PubMed ID: 32296971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial appendage closure device implantation in patients with prior intracranial hemorrhage.
    Hutt E; Wazni OM; Saliba WI; Kanj M; Tarakji KG; Aguilera J; Barakat AF; Rasmussen P; Uchino K; Russman A; Hussain S; Wisco D; Kapadia S; Lindsay BD; Hussein AA
    Heart Rhythm; 2019 May; 16(5):663-668. PubMed ID: 30521942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Chinese Patients with Nonvalvular Atrial Fibrillation: A Single-center, Prospective, Observational Study.
    Huang WP; Zhang YH; He L; Su X; Yang XW; Guo ZX
    Chin Med J (Engl); 2017 Feb; 130(4):434-438. PubMed ID: 28218217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up.
    Phillips KP; Pokushalov E; Romanov A; Artemenko S; Folkeringa RJ; Szili-Torok T; Senatore G; Stein KM; Razali O; Gordon N; Boersma LVA
    Europace; 2018 Jun; 20(6):949-955. PubMed ID: 29106523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
    Maksym J; Mazurek T; Kochman J; Grygier M; Kapłon-Cieślicka A; Marchel M; Lodziński P; Piątkowski R; Wilimski R; Czub P; Fojt A; Karolczak N; Hendzel P; Opolski G
    Kardiol Pol; 2018; 76(2):459-463. PubMed ID: 29350390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of sex differences on outcomes in patients with non-valvular atrial fibrillation undergoing left atrial appendage closure: A single-center experience.
    Zhao M; Post F; Muenzel M; Hou CR; Keil T; Yu J
    Int J Med Sci; 2021; 18(9):1990-1998. PubMed ID: 33850469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with the WATCHMAN™ left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry.
    Bonnet G; Salaun E; Pankert M; Cuisset T; Bonnet JL
    Arch Cardiovasc Dis; 2016 Dec; 109(12):689-695. PubMed ID: 27594651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of left atrial appendage closure in atrial fibrillation patients with different types of heart failure.
    Liu L; Yan W; Xu X; Wan C; Liu F; Yao Q; Song L; Wang B; Song Z; Li H
    BMC Cardiovasc Disord; 2024 Aug; 24(1):430. PubMed ID: 39148039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous Left Atrial Appendage Closure with WATCHMAN™ device: peri-procedural and mid-term outcomes from the TRAPS Registry.
    Mazzone P; D'Angelo G; Regazzoli D; Molon G; Senatore G; Saccà S; Canali G; Amellone C; Turri R; Bella PD
    J Interv Card Electrophysiol; 2018 Jun; 52(1):47-52. PubMed ID: 29525913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of the presence of chronic kidney disease on percutaneous left trial appendage closure for atrial fibrillation: A single center experience.
    Benini Tapias J; Flores-Umanzor E; Cepas-Guillén PL; Regueiro A; Sanchís L; Broseta JJ; Cases A; Freixa X
    Nefrologia (Engl Ed); 2022; 42(3):290-300. PubMed ID: 36210618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMAN™ device.
    Luani B; Genz C; Herold J; Mitrasch A; Mitusch J; Wiemer M; Schmeißer A; Braun-Dullaeus RC; Rauwolf T
    BMC Cardiovasc Disord; 2019 May; 19(1):112. PubMed ID: 31092201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation.
    Dognin N; Salaun E; Champagne C; Domain G; O'Hara G; Philippon F; Paradis JM; Faroux L; Beaudoin J; O'Connor K; Bernier M; Rodés-Cabau J; Champagne J
    J Interv Card Electrophysiol; 2022 Aug; 64(2):497-509. PubMed ID: 34822043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of contrast-free left atrial appendage closure with WATCHMAN FLX device for patients with chronic kidney disease.
    Okada A; Kubo S; Chatani R; Mushiake K; Nishiura N; Ono S; Maruo T; Kadota K
    Cardiovasc Interv Ther; 2024 Apr; 39(2):191-199. PubMed ID: 38064131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.